Rep. Josh Gottheimer Sells Off Shares of Natera, Inc. (NASDAQ:NTRA)

Key Points

• Representative Josh Gottheimer sold between $1,001 and $15,000 in shares of Natera, Inc. on July 22nd, as part of a series of trades including other major companies like Walmart and IBM.
• Natera recently reported a loss per share of ($0.74), which missed consensus estimates and reflects a negative return on equity of 22.22%, despite a year-over-year revenue increase of 32.2% to $546.60 million.
• Equity analysts are generally optimistic about Natera, with 16 analysts giving a buy rating and price targets ranging up to $255.00, while the average target price is $193.87.

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Natera, Inc. NASDAQ: NTRA. In a filing disclosed on August 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Natera stock on July 22nd. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Walmart NYSE: WMT on 7/28/2025.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 7/25/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/18/2025.
• Sold $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 7/16/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 7/14/2025.
• Sold $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/2/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/25/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 6/24/2025.

Natera Stock Up 2.9%

NASDAQ:NTRA traded up $4.58 during trading hours on Friday, reaching $163.02. 1,502,326 shares of the stock were exchanged, compared to its average volume of 1,693,905. The firm has a 50 day simple moving average of $155.18 and a 200-day simple moving average of $154.75. Natera, Inc. has a 52 week low of $110.57 and a 52 week high of $183.00. The stock has a market capitalization of $22.37 billion, a P/E ratio of -85.35 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%. The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the business earned ($0.30) EPS. The company's quarterly revenue was up 32.2% on a year-over-year basis. As a group, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research reports. Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a research report on Friday. Cowen restated a "buy" rating on shares of Natera in a research report on Friday, August 8th. Piper Sandler restated an "overweight" rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Royal Bank Of Canada raised their target price on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. One analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and a consensus target price of $193.19.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. The trade was a 4.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,792 shares of company stock valued at $9,227,972. Company insiders own 5.63% of the company's stock.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. LRI Investments LLC bought a new stake in shares of Natera during the 4th quarter worth $29,000. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the 1st quarter worth about $29,000. Rakuten Securities Inc. boosted its stake in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new position in shares of Natera in the first quarter worth about $32,000. Finally, TCTC Holdings LLC increased its stake in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares during the period. 99.90% of the stock is owned by institutional investors.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.